Evidence map›Paper›PMID 42910275›Full record

ArticleInternational journal of biological sciences2026

Extracellular Vesicles from Human Induced Pluripotent Stem Cells Reduce Lung Ischemia-Reperfusion Injury via Cytoprotective Mechanisms in both 2D Cultures and a Human Airway Organoid Model.

Rosaria Tinnirello, Maria Chiara Iachini, Maura Cimino, Noemi Elia, Margot Lo Pinto, Simone Dario Scilabra, Gioacchin Iannolo, Giovanni Zito, Roberta Vazzana, Nicola Cuscino and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Rosaria TinnirelloResearch Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione), Palermo, Italy.
Maria Chiara IachiniUnit of Cell and Gene Therapies, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Maura CiminoResearch Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione), Palermo, Italy.
Noemi EliaUnit of Cell and Gene Therapies, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Margot Lo PintoRi.MED Foundation, Palermo, Italy.
Simone Dario ScilabraRi.MED Foundation, Palermo, Italy.
Gioacchin IannoloResearch Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione), Palermo, Italy.
Giovanni ZitoResearch Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione), Palermo, Italy.
Roberta VazzanaResearch Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione), Palermo, Italy.
Nicola CuscinoResearch Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione), Palermo, Italy.
Matteo BulatiResearch Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione), Palermo, Italy.
Tuğba Dursun UsalRi.MED Foundation, Palermo, Italy.
Federica CosentinoRi.MED Foundation, Palermo, Italy.
Antonio D'amoreRi.MED Foundation, Palermo, Italy.
Federica GuffantiLaboratory of Gynecological Preclinical Oncology, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Giovanna DamiaLaboratory of Gynecological Preclinical Oncology, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Vincenza DoloDipartimento di Medicina Clinica, Sanità Pubblica, Scienze della Vita e dell'Ambiente, Università de L'Aquila, L'Aquila, Italy.
Massimo PinzaniResearch Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione), Palermo, Italy.
Pier Giulio ConaldiResearch Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione), Palermo, Italy.
Alessandro BertaniUniversità degli Studi di Enna "Kore", Enna, Italy.
Lorenzo RossoUnit of Thoracic Surgery and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Lorenza LazzariUnit of Cell and Gene Therapies, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Vitale MiceliResearch Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione), Palermo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung transplantation (LTx) remains the only curative option for patients with end-stage pulmonary diseases. However, long-term outcomes are compromised by ischemia-reperfusion injury (IRI), a major contributor to primary graft dysfunction and chronic lung allograft impairment. Current pharmacological and technological strategies provide only partial protection, highlighting the need for novel therapeutic approaches. In this study, we investigated the therapeutic potential of extracellular vesicles derived from human induced pluripotent stem cells (hiPSC-EV) in a two-dimensional (2D)

Indexed as

Extracellular VesiclesInduced Pluripotent Stem CellsLungOrganoidsReperfusion InjuryAnimalsApoptosisCell SurvivalHumansOxidative StressReactive Oxygen SpeciesReactive Oxygen Species3D models, organoidsextracellular vesiclesiPSC.ischemia-reperfusion injurylung transplantation

Identifiers

PMID42910275
PMCPMC13685754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.